1 Full title: Lifecourse Genome-Wide Association Study Meta-Analysis Refines the Critical Life
2 Stages for Adiposity's Influence on Breast Cancer Risk
3
4 Short title: Lifecourse Influence of Adiposity on Breast Cancer
5

6 Authors: Grace M. Power[1,2,3], Laxmi Bhatta[4,5,6], Amanda M. Hughes[1,2,7], Carolina Medina-
7 Gomez[8], Anne Richmond[9], Genevieve Leyden[1,2], Bethan Lloyd-Lewis[1,10], Eleanor Sanderson[1,2],
8 Rebecca Richmond[1,2], Elizabeth C. Corfield[1,2,7,11], Daniel McCartney[9], Caroline Hayward[9,12],
9 Irene Fontes Marques[13,14], Fernando Rivadeneira[8], Bjørn Olav Åsvold[4,15,16], Gibran Hemani[1,2],
10 Janine F. Felix[13,14], Ben Brumpton[4,15,17], Alexandra Havdahl[7,11,18], George Davey Smith[1,2,19]
11
Affiliations
1. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
2. Population Health Sciences, Bristol Medical School, University of Bristol, UK.
3. Institute for Molecular Bioscience, The University of Queensland, Brisbane,
Queensland, Australia.
4. HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and
Nursing, NTNU Norwegian University of Science and Technology, Trondheim, Norway.
5. Division of Mental Health Care, St Olavs Hospital, Trondheim, Norway.
6. Department of Clinical and Molecular Medicine, NTNU Norwegian University of Science
and Technology, Trondheim, Norway.
7. PsychGen Centre for Genetic Epidemiology and Mental Health, Norwegian Institute of
Public Health, Oslo Norway.
8. Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam,
Rotterdam, CA 3000, The Netherlands.
9. Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, The
University of Edinburgh, Edinburgh, UK.
10. School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
11. Research Department, Lovisenberg Diaconal Hospital, Oslo, Norway
12. MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh,
Western General Hospital, Edinburgh, UK.
13. Generation R Study Group, Erasmus MC, University Medical Center Rotterdam,
Rotterdam, the Netherlands.
14. Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam,
Rotterdam, the Netherlands.
15. HUNT Research Centre, Department of Public Health and Nursing, NTNU Norwegian
University of Science and Technology, Levanger, Norway.
16. Department of Endocrinology, Clinic of Medicine, St. Olavs Hospital, Trondheim
University Hospital, Trondheim, Norway.
17. Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim,
Norway.
18. PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo,
Norway
19. NIHR Bristol Biomedical Research Centre Bristol, University Hospitals Bristol and
Weston NHS Foundation Trust, University of Bristol, Bristol, UK.

Abstract

Previous evidence suggests that higher prepubertal adiposity protects against breast cancer
risk. Whether this protection extends into early adulthood remains uncertain. We conducted
genome-wide association studies on body mass index (BMI) in nulliparous women from
menarche to <40 years across five cohorts, with additional analyses in three sub-intervals of
this life stage. Results were meta-analysed, and two-sample univariable and multivariable
Mendelian randomisation was applied within a lifecourse framework to assess the effect of
BMI on breast cancer risk. Between menarche and <40 years, we observed heterogeneity in
genetic effects. Genome-wide correlations further suggest BMI during this early adult period
may be partly influenced by distinct genetic factors compared with adiposity at other life
stages. Higher genetically proxied BMI between menarche and 40 years reduced breast cancer
risk. This protective effect attenuated after adjusting for prepubertal adiposity. These findings
refine our understanding of adiposity's role in breast cancer and highlight earlier life stages as
critical windows for risk modulation.

Teaser

Improving knowledge of adiposity's genetic architecture across the lifecourse refines insights
into its role in breast cancer

Introduction

Breast cancer is the most commonly diagnosed cancer in women worldwide, with over 2.3 million new cases and 685,000 deaths reported in 2020 (*1*). Nearly 99% of women diagnosed at the earliest stage survive for 5 years or more, compared to approximately 32% of those diagnosed at the most advanced stage (*2*). This underscores the importance of improving early detection and highlights the need to identify preventative strategies as key public health objectives.

Breast tissue is particularly vulnerable to exposures between menarche and first full-term pregnancy – a critical window of susceptibility (*3*). After menarche, the breast epithelium undergoes rapid cellular proliferation leading to an increased risk of acquiring mutation during puberty and until the terminal ductal differentiation that accompanies the first full-term pregnancy (*4, 5*). Evidence suggests that certain exposures such as physical activity (*3*), may alleviate the risk of breast cancer, while others, such as alcohol consumption (*6*), a known breast carcinogen (*7*), may exacerbate it, by acting during this period of tumorigenic susceptibility. By investigating whether known factors influencing breast cancer risk also exert effects during this timeframe, we may be better able to identify strategies for more effective breast cancer risk detection and potential avenues for prevention. Focusing on this period may additionally enable a more precise assessment by minimising the confounding effects of physiological changes associated with first birth.

Mendelian randomization (MR) is a technique that exploits the quasi-random distribution of genetic variants from parents to offspring, independent of the influence from other traits. Under specific assumptions, MR aims to estimate causal effects by reducing susceptibility to confounding factors, including confounding by undiagnosed existing disease and disease processes (reverse causation) (*8, 9*). Recent developments in lifecourse MR methodology include multivariable MR (MVMR) (*10-12*). This approach enables the direct estimation of the effects of an exposure measured at a specific life stage, controlling for the same exposure measured at another life stage, on later life outcomes. Previous MVMR analyses suggest that a larger prepubertal body size, employed as a proxy for BMI, is protective against breast cancer (*13-16*). This protective effect persists even after controlling for later life adult body size, which has a negligible effect on breast cancer risk when prepubertal body size is controlled for. These findings align with conventional analyses (*17-23*) and have been further supported through a proxy-genotype MR approach, where offspring genotype proxies parental genotype to assess associations with parental disease risk (*24*). It has been proposed that such findings may be influenced by selection bias, as both childhood adiposity and breast cancer status could affect the likelihood of surviving to or participating in large-scale cohort studies (*25*). However, simulations examining the relationship between childhood body size and subsequent breast cancer risk indicate that, although bias can arise – particularly under interaction-driven

selection (*26*) – the magnitude remains insufficient to account for the protective effects observed in MR analyses (*27*).

Although a larger body size in childhood has been shown to reduce breast cancer risk, it also leads to earlier menarche, a known risk factor for breast cancer (*13*). This dual effect suggests that the protective direct effect of prepubertal body size on breast cancer could be larger than its total observed effect, as it may be partially attenuated by an increased risk mediated through earlier menarche. This interplay highlights two potentially independent pathways that may interact in complex ways. Despite convincing evidence for the protective effects of prepubertal body size on breast cancer risk, the time period at which this protective effect diminishes is yet to be determined using causal inference methods.

We aimed to estimate the effect of higher BMI between menarche and first full-term pregnancy – or throughout early adulthood (<40 years) in individuals who remain nulliparous – on breast cancer risk later in life. This previously understudied period represents a critical window of susceptibility to exposures influencing breast cancer risk. We first conducted genome-wide association studies (GWAS) of BMI in nulliparous women from five population-based cohorts across the full period from menarche to <40 years, and then stratified the analyses into three groups: menarche to <20 years, 20 to <30 years, and 30 to <40 years. This approach allowed us to assess the consistency of genetic variant effects on BMI across early adulthood and to apply these profiles in downstream lifecourse MR analyses. We then assessed these effects on overall breast cancer and different subtypes, including ER status (ER+/ER-) and five molecular subtypes: Luminal A-like, Luminal B-like (HER2-positive), Luminal B (HER2-negative-like), HER2-enriched, and triple-negative breast cancer using data from the Breast Cancer Association Consortium (BCAC) (*28, 29*). While we were not able to assess effects by menopausal status directly, we examined subtype-specific effects as a means of providing preliminary insights given that certain subtypes are more commonly diagnosed before or after menopause.

Results

Measurements of body mass index (BMI) between menarche and age <40 years were available for 56,863 nulliparous women across five cohorts: the Avon Longitudinal Study of Parents and Children (ALSPAC), the Trøndelag Health Study (HUNT), the Norwegian Mother, Father and Child Cohort Study (MoBa), Generation R, and Generation Scotland. Corresponding phenotype sample sizes and cohort characteristics for age and BMI are presented in Table 1. Within the primary <40 year group, mean ages at measurement ranged from 23.9 years in ALSPAC to 29.4 years in Generation R, while mean BMI values varied between 22.8 kg/m² in ALSPAC and 24.5 kg/m² in Generation Scotland. To explore patterns across narrower age intervals within this broader period, we also conducted analyses stratified into three groups: menarche to <20 years, 20 to <30 years, and 30 to <40 years. Phenotypic sample sizes and summary measures of age and BMI for the full <40 group and each stratum are shown in Table 1.

Table 1. Descriptive statistics for nulliparous women between menarche and <40 years, menarche and <20 years, 20 and <30 years and 30 and <40 years, across all cohorts.

	Cohort	N	Age (years)		BMI (kg/m²)	
			Mean (SD)	Median (Min-Max)	Mean (SD)	Median (Min-Max)
ALL (MENARCHE TO <40 YEARS)	ALSPAC	5047	23.92 (6.01)	24.00 (14.00-39.00)	22.79 (3.86)	21.98 (12.50-51.16)
	HUNT	7683	24.40 (5.04)	23.7 (12.80-39.90)	23.40 (3.99)	22.50 (15.34-52.20)
	MoBa	38687	25.75 (6.68)	27.00 (14.00-39.00)	23.16 (4.01)	22.38 (8.11-46.07)
	Generation R	2396	29.44 (4.71)	30.13 (15.96-39.95)	23.07 (4.04)	22.09 (14.53 - 49.82)
	Generation Scotland	3059	26.29 (5.95)	26.00 (14.00-39.00)	24.52 (5.28)	23.24 (13.13-57.94)
MENARCHE TO <20 YEARS	ALSPAC	2047	17.78 (0.42)	17.75 (14.00-19.33)	22.79 (4.10)	21.92 (13.11-50.06)
	HUNT	1093	16.90 (2.01)	17.00 (12.80-19.90)	21.95 (3.07)	21.48 (15.34-46.87)
	MoBa	7834	14.74 (1.22)	14.00 (14.00-19.00)	20.91 (3.06)	20.45 (8.92-40.75)
	Generation R					
	Generation Scotland	430	18.15 (0.94)	18.00 (14.00-19.00)	22.88 (3.96)	22.05 (15.5-43.09)
20 TO <30 YEARS	ALSPAC	3520	24.91 (2.12)	24.00 (20.00-29.00)	23.61 (4.44)	22.52 (14.22-57.88)
	HUNT	5507	24.18 (2.69)	23.70 (20.00-29.90)	23.50 (3.99)	22.7 (15.60-52.20)
	MoBa	18578	25.86 (2.51)	26.00 (20.00-29.00)	23.66 (4.05)	22.78 (8.11-45.31)
	Generation R	1127	26.08 (2.86)	26.62 (20.01 - 29.99)	23.24 (4.47)	22.20 (14.53 - 49.82)
	Generation Scotland	1745	24.41 (2.81)	24.00 (20.00-29.00)	24.31 (5.03)	23.12 (13.13-54.95)
30 TO <40YEARS	ALSPAC	1054	32.65 (2.45)	32.00 (30.00-39.00)	22.72 (3.65)	21.97 (12.50-47.30)
	HUNT	1083	33.09 (2.60)	32.30 (30.00-39.90)	24.32 (4.45)	23.30 (17.00-48.50)
	MoBa	12275	32.61 (2.38)	32.00 (30.00-39.00)	23.84 (3.97)	22.99 (8.50-46.07)
	Generation R	1269	33.12 (2.25)	32.76 (30.00 - 39.95)	22.98 (3.67)	22.06 (16.90 - 43.34)
	Generation Scotland	884	33.98 (2.85)	34.00 (30.00-39.00)	25.72 (6.00)	24.05 (13.7-57.94)

Lifestage-stratified genome-wide association studies (GWAS) and meta-analysis

Genome-wide association analyses (GWAS) for BMI were conducted in up to 56,628 nulliparous women with measures between menarche and age <40 years, and results were meta-analysed across cohorts. Stratified meta-analyses for the three life stages – menarche to <20 years, 20 to <30 years, and 30 to <40 years – included 11,365, 30,272 and 16,565, respectively (Figure 1). For cohorts with repeat measures within one life stage (e.g., menarche to <40 years), we retained the time point with the largest sample size (e.g., for ALSPAC, only BMI data from participants <20 years were included). Considering results across all GWAS time windows (menarche to <20, 20 to <30, 30 to <40, and the combined menarche to <40), we identified a total of 45 independent variants.

Number of female participants with genotype data and BMI measured while nulliparous, by age category [a]

Menarche to <20 years				
ALSPAC	HUNT	n MoBa	Generation R	Generation Scotland
2,047	1,093	7,834	N/A	391

20 to <30 years				
ALSPAC	HUNT	n MoBa	Generation R	Generation Scotland
3,520	5,507	18,578	1,127	1,540

30 to <40 years				
ALSPAC	HUNT	n MoBa	Generation R	Generation Scotland
1,054	1,083	12,275	1,269	884

Number of female participants with genotype data and BMI measured while nulliparous between menarche and <40 years [b]

ALSPAC	HUNT	n MoBa	Generation R	Generation Scotland
5,047	7,683	38,687	2,396	2,815

a. this includes cohorts with repeat measures in the same individual for each age group category, b. for cohorts with repeat measures, this takes one measure within the age group with the largest sample size (e.g., for ALSPAC it only includes offspring BMI data from menarche to <20 year olds).

162
163
Figure 1. Overview of study participants used for this analysis

Overall, 31, 3, 12, and 5 lead genetic variants were identified as associated with BMI in
nulliparous women between menarche to <40 years, menarche to <20 years, 20 to <30 years,
and 30 to <40 years prior to giving birth, respectively, based on conventional genome-wide
significance (P<5×10⁻⁸) and LD clumping within each life stage to identify conditionally
independent signals (Table S1). Because clumping was conducted independently for each time
window, some loci are likely represented by different lead SNPs across groups, reflecting
tagging of the same underlying association signal. Additionally, because the narrower age
windows are nested within the broader menarche to <40 group, many SNPs identified in the
subgroups, or SNPs in high LD with them, also appear in the full-period analysis.

In total, 45 unique SNPs were identified across all groups. Nine loci reached genome-wide
significance in every life-stage GWAS (menarche to <40 years, <20 years, 20 to <30 years, and
30 to <40 years). Additional overlap was observed between the combined menarche to <40
years analysis and the stratified groups, with 9 loci genome-wide significant in both the
combined and <20 years groups, 26 in both the combined and 20 to <30 years groups, and 13
in both the combined and 30 to <40 years groups. Although such overlap is expected given the
nested design, these findings indicate that, while some loci were detected only within certain
intervals, a core set of loci consistently associated with BMI across adolescence and early
adulthood.

To assess redundancy and overlap across stages, we applied LD clumping to the compilation of
all 45 SNPs retained after stage-specific clumping. This revealed that they correspond to 31
independent genomic regions, indicating that several loci are shared across groups despite
being tagged by different SNPs. The majority of these independent signals were identified
within the menarche to <40 group, which is expected given its larger sample size and broader
coverage. SNPs that remained in the final set of 31 independent regions are marked in Table
S1.

Cochran's Q statistic was used to evaluate heterogeneity in SNP-exposure associations across
the five cohort studies included in the primary analysis. To account for multiple testing across
the 31 SNPs, a Bonferroni correction was applied. After adjustment, none of the variants
showed evidence of heterogeneity (Q_{bonf}<0.05), suggesting consistent effect estimates across
studies. This reinforces their validity in downstream MR analyses, reducing concerns
that study-level differences may confound associations with the outcome. Full heterogeneity
results, including uncorrected P-values and Q statistics, are provided in Table S2.
197
We visualised the life stage-specific effect trajectories of these SNPs at each life stage
(menarche to <20 years, 20 to <30 years and 30 to <40 years), with point size inversely
proportional to the standard error of the effect estimate (Figure S1). This revealed two notable
patterns of heterogeneity: (i) SNP effects in the 20 to <30-year life stage differ markedly from
those in the menarche to <20-year and 30 to <40-year life stages, and (ii) some SNPs show a
reversal in effect after age 30. Among 45 independent variants, nine showed substantial

heterogeneity across the three life stages (Q_{het}<0.05) (Figure 2). Given that the proportion of individuals from each cohort is comparable between the 20 to <30-year and 30 to <40-year life stages, the shift in effect estimates observed in the 20 to <30-year group is unlikely to be driven by a single cohort. These distinct patterns underscore age-specific heterogeneity that would likely be overlooked by linear meta-regression, highlighting the complexity of SNP effects on BMI over time.

Figure 2. Plot illustrating the age-specific effect trajectories of individual SNPs with significant heterogeneity (QFDR < 0.05) on BMI across three defined life stages: menarche to <20 years, 20 to <30 years, and 30 to <40 years, in nulliparous women. Each plot represents a SNP exhibiting significant heterogeneity (QFDR < 0.05), illustrating its effect size (beta) across life stages. Error bars denote 95% confidence intervals.

Heritability, LD score regression and genetic correlation analysis

We quantified the proportion of variance of the four meta-analyses undertaken on BMI in nulliparous women at different ages of European ancestry that can be explained by our SNP sets using Linkage Disequilibrium (LD) Score regression (*30*). The GWAS summary statistic SNP-based heritability ranged from 0.11 (SE = 0.01) for BMI in nulliparous women between 30 and <40 year olds, to 0.23 (SE = 0.02) for BMI in nulliparous women between 20 to <30 year olds (Table 2). These results indicate that genetic factors play an important role in BMI, particularly

223   in the younger life stages. The number of GWAS hits aligns with expectations, closely tracking
224   with heritability (h^2) and sample size, suggesting consistent polygenicity across life stages.

225   Table 2. Summary of meta-analysed genome-wide association results by life stage categories.
226

	Age group category			
Metric	BMI in nulliparous women between menarche and <40 years	BMI in nulliparous women between menarche and <20 years	BMI in nulliparous women between 20 and <30 years	BMI in nulliparous women between 30 and <40 years
	Estimate (SE)	Estimate (SE)	Estimate (SE)	Estimate (SE)
Heritability (Observed Scale h²)	0.19 (0.01)	0.21 (0.03)	0.23 (0.02)	0.11 (0.01)
Genomic Inflation Factor (Lambda GC)	1.27	1.07	1.17	1.09
LD Score Regression Intercept	1.01 (0.01)	1.01 (0.01)	1.00 (0.01)	1.01 (0.01)
Proportion of Inflation (Ratio)	0.03 (0.02)	0.13 (0.08)	0.01 (0.04)	0.07 (0.06)

The genetic correlations (r_G) observed between prepubertal body size (used as a proxy for BMI)
in females and BMI at different stages in nulliparous women from menarche to <40 years
reveal consistently strong associations, as expected when investigating a similar phenotype
(BMI and body size) across different life stages. The r_G of 0.76 (SE = 0.02, P = 2.13x10^{-223})
between prepubertal body size in females and BMI in nulliparous women <40 years indicates
a high degree of shared genetic influence. This trend was mirrored at more granular age
intervals, with r_G values of 0.88, 0.74, and 0.71 for BMI in nulliparous women from menarche
to <20, 20 to <30, and 30 to <40 years, respectively (Figure 3). These results suggest
prepubertal body size has a slightly stronger genetic correlation in younger life stages,
particularly for BMI measured before age 20. Similarly, body size (used as a proxy for BMI) in
later life adult women shows strong genetic overlap with BMI measured in nulliparous women
at various age periods, with rG values ranging from 0.68 (for BMI in nulliparous women from
menarche to <20 years) to 0.95 (for BMI in nulliparous women aged 30 to <40 years). The
consistently high rG values across all comparisons, particularly the near-perfect correlation
between body size measured in later life adult women and BMI in nulliparous women aged 30
to <40 (rG = 0.95, SE = 0.05), may reflect an enduring genetic influence of BMI from
adolescence into later reproductive years (Figure 3; Table S3). The genetic correlation is
unaffected by differences in measurement scale, as it reflects shared genetic architecture
rather than observed variance. One r_G estimate calculated using LDSC slightly exceeded 1,
which is a known feature of the method due to sampling variability and its unconstrained
estimation framework. This value is not represented in the figure but is included in Table S3,
where all r_G values are reported. While overlapping samples can contribute to inflation, LDSC
intercepts adjust for this, and such values are not necessarily indicative of bias or
methodological error.

Figure 3. Genetic correlation heatmap for body mass index (BMI) and body size (used as a proxy
for BMI) across various life stages in females, spanning from prepuberty through menarche and
first birth to later adulthood.
256
257   *Lifecourse Mendelian randomization (MR) analysis*
258
Univariable MR analyses indicated evidence that a one standard deviation (SD) increase in
genetically predicted log-transformed BMI in nulliparous women between menarche and <40
years reduced the risk of overall breast cancer (IVW odds ratio (OR), 95% CI: 0.76, 0.67 to 0.86,
P=1.27x10^{-5}) (Figure 4; Table S4). Similar inverse effects were observed across most breast
cancer subtypes, except for the HER2-enriched subtype, which showed little evidence of
protection. In multivariable MR accounting for later life adult body size, higher genetically
predicted BMI in this window continued to provide evidence of a reduced risk of overall breast
cancer and most subtypes, with HER2-enriched disease remaining the exception. Adjustment
for prepubertal body size led to a marked, though not complete, attenuation of these effects,
consistent with part of the protection being shared with childhood adiposity. Some evidence
of a protective effect was observed for Luminal B-like (HER2+) tumours (Figure 4; Table S4).
270
271   In the narrower life-stage periods obtained by partitioning the broader fertile-window
272   measure, univariable MR analyses indicated evidence that higher genetically predicted BMI in

nulliparous women between menarche to <20, 20 to <30, and 30 to <40 years reduced the risk of overall breast cancer and most subtypes, although the strength and precision of effects varied by subtype and life-stage period. After accounting for later life adult body size, protective effects were largely retained, with most estimates still supporting a reduction in risk. In contrast, adjusting for prepubertal body size removed much of the apparent protection in these narrower periods. For triple-negative disease, effect estimates suggested modest residual protection in the 20 to <30 window after accounting for childhood body size. Weighted median estimates were consistent in direction and magnitude. MR-Egger analyses provided little evidence of horizontal pleiotropy for the combined menarche to <40 exposure; for the narrower life-stage windows, estimates were imprecise due to limited statistical power (Table S4). To further assess the validity of the inferred causal direction, we applied Steiger filtering, which tests whether the genetic instruments explain more variance in the exposure than in the outcome. Across all life stages, the proportion of variance explained (R^2) was consistently higher for BMI than for breast cancer, supporting the hypothesised direction of effect from BMI to breast cancer (Table S5).

Using Mendelian Randomization Robust Adjusted Profile Score (MR-RAPS) with an instrument selection threshold of $P < 1 \times 10^{-5}$, genetically predicted BMI between menarche and <40 years, as well as between 20 and <30 years, showed strong evidence of a protective effect on overall breast cancer risk. Weaker evidence was observed for BMI between 30 and <40 years, while very little evidence of an effect was found for BMI between menarche and <20 years (Table S6).

Multivariable MR results should be interpreted with caution since conditional F-statistic was <10 for each of the BMI exposures included in these models, indicating potential for weak instrument bias (Table S4).

Figure 4. Univariable and multivariable Mendelian randomization (MR) for BMI between menarche and first birth on breast cancer (overall and subtype samples). A. The total effects (univariable MR). B. The direct effect accounting for childhood body size, and C. The direct effect accounting for later life adulthood body size (multivariable MR (MVMR)). The plots present the odds ratio of breast cancer per standard deviation (SD) increase in natural log-transformed BMI. Error bars indicate 95% confidence intervals around the point estimate from inverse-variance weighted (IVW) MR and IVW-MVMR analyses.

Sensitivity analyses

To minimise pregnancy-related confounding, we restricted the BMI GWAS to nulliparous women, which enabled a clearer assessment of BMI's direct influence across life stages. However, this restriction may introduce selection (collider) bias (*31*) if genetically proxied parity is associated with BMI within the nulliparous sample, as parity was not conditioned on in the breast cancer outcome GWAS. Our analyses indicated very little evidence that genetically proxied parity associated with BMI in nulliparous women between menarche and <40 years, menarche and <20 years, and 20 and <30 years. There was some evidence that genetically proxied parity associated with lower BMI in nulliparous women between 30 and <40 years (Table S7). There was very little evidence of effect in the reverse direction (BMI-associated variants on parity). These results suggest collider bias due to selecting nulliparous women is likely to be of little concern within this study.

323 After adjusting for age at menarche, the estimated effect of BMI in nulliparous women
324 between menarche and <40 years on overall breast cancer remains largely consistent with the
325 UVMR analyses (Table S8). Age at menarche itself showed little direct effect on overall breast
326 cancer or most subtypes once BMI was accounted for.

Discussion

In this study, we undertook GWAS and MR analyses within a lifecourse framework to (i) assess the consistency of the genetic effects of BMI across different life stages, and (ii) investigate the effects of genetically proxied BMI in nulliparous women between menarche and <40 years on the risk of overall breast cancer and seven subtypes. This work builds on previous research to further the investigation into the influence of BMI during critical periods on breast cancer risk (13, 14, 32). Motivated by recent findings suggesting that a larger prepubertal body size, used as a proxy for BMI, may offer protection against breast cancer risk, while later life body size shows very little effect, we aimed to better understand the interval between puberty and later life. Specifically, we focused on the period between menarche and first full-term pregnancy, a crucial window of vulnerability for later life breast cancer development.

We observed variation in genetic effects on BMI across different life stages for nine of the 45 discovery variants identified in this study. Some of this variation may reflect statistical fluctuation introduced by selecting lead SNPs based on age-stratified significance thresholds. However, several variants showed clear changes in the direction of effect across the life stage groups. These directional shifts are unlikely to be due to random variation alone and suggest that the influence of certain genetic variants on BMI may differ depending on developmental stage. In addition, genome-wide cross-lifestage genetic correlations demonstrated variation, e.g., when comparing prepubertal body size and later life body size with BMI from menarche to <40 years.

In the univariable MR analyses, higher BMI in nulliparous women from menarche to <40 years was found to consistently reduce risk of overall breast cancer and most subtypes. Similar protective effects were observed when BMI was measured within narrower periods of this window (menarche to <20, 20 to <30, and 30 to <40 years). These protective effects largely remained after accounting for later life adult body size. In contrast, adjusting for prepubertal body size in multivariable MR led to greater attenuation, indicating that part of the protective effect of BMI in early reproductive life may be explained by body size before puberty. The attenuation was more pronounced for the narrower life-stage periods than for the full fertile-window measure, reflecting both biological and methodological influences. Biologically, part of the apparent effect across all reproductive-age windows overlaps with childhood adiposity, so adjustment for prepubertal body size reduces the estimates. Methodologically, the narrower age-specific GWASs have substantially smaller sample sizes than the childhood GWAS. In multivariable MR, this imbalance can magnify the degree of attenuation by limiting power to detect effects independent of childhood size. By contrast, the broader reproductive-age measure is based on a larger GWAS sample and therefore shows less attenuation, despite adjustment for the same childhood body size data. Importantly, no such attenuation was observed when adjusting for later-life body size, even though similar sample size imbalances exist. This indicates that differential power alone may not fully explain the observed

368   differences. Future methodological work is needed to examine how sample size disparities
369   across life-stage GWASs influence estimates in multivariable MR and to develop strategies for
370   accounting for this in lifecourse applications.
371
Our findings are in line with previous MR and conventional epidemiological studies reporting a
strong protective effect of early-life adiposity on breast cancer risk (*13-24*). Simulations
suggest that selection bias alone is unlikely to account for this association (*27*). Although bias
arose, it fell short of the effect sizes reported in earlier work. This study extends these earlier
analyses by exploring adiposity at additional life stages. The attenuation of associations with
post-menarche BMI after adjusting for prepubertal body size suggests that earlier adiposity
may, at least in part, confound estimates for later periods. Given that the protective effect of
early-life adiposity is unlikely to arise from selection bias alone, these results reinforce the
importance of accounting for early-life exposures when evaluating causal effects across the
lifecourse.
382
Evidence suggests that two distinct early-life pathways influence breast cancer risk: one linked
to greater body size and the other to earlier age at menarche (*13*). While a larger body size in
early life appears protective, it may also accelerate age at menarche, which is itself a risk factor
for breast cancer, suggesting that these pathways are not only independent but may interact
in complex ways. To isolate the direct effect of BMI independent of pubertal timing, we applied
MVMR controlling for age at menarche. However, the genetic architecture of age at menarche
and early-life adiposity overlaps substantially (*33*). A recent genome-wide structural equation
model integrating MoBa childhood BMI, recalled adiposity at age 10 in UK Biobank, and age at
menarche estimated that nearly half of the genetic variants associated with menarche act
through early-life adiposity (*33, 34*). This overlap has also been supported by longitudinal twin
studies (*35*). While this indicates strong shared genetic pathways, a proportion of menarche-
associated variants likely do act independently of adiposity. Nonetheless, BMI-related
pathways to earlier menarche may contribute more strongly to identified SNP signals than non-
BMI influences, complicating interpretation of MVMR estimates. Thus, although MVMR
provides a valuable sensitivity analysis, it may not fully disentangle the independent
contributions of adiposity and pubertal timing, particularly where shared pathways act
differently across breast cancer subtypes. Furthermore, increased prepubertal body size has
been shown to decrease breast density, while age at menarche has been linked to higher
breast density, which is another important risk factor for breast cancer (*32, 36*). This distinction
between pathways highlights the need to examine potential mediating factors, which may help
clarify the mechanisms at play. A deeper investigation into these separate but intersecting
pathways could reveal novel insights into breast cancer risk.
405
The relationship between body size and breast cancer risk is further complicated by
menopausal status. In conventional epidemiological settings, higher BMI has been linked to an
increased risk of breast cancer in postmenopausal women and a decreased risk of breast

cancer in premenopausal women (*37-40*). A plausible explanation includes the differing levels
of oestrogen exposure between women experiencing overweight and normal-weight (*41*).
Premenopausal women experiencing overweight tend to have longer anovulatory cycles,
which reduces their exposure to ovarian hormones, potentially lowering their breast cancer
risk. After menopause, fat tissue serves as another source of oestrogen production, which
increases breast cancer risk among overweight women (*42-45*). Whilst our study did not
specifically examine the relationship between overweight status and breast cancer pre- and
post- menopause, effect estimates were broadly consistent across subtypes, with only modest
differences in magnitude. The most evident departure from this pattern was seen in the HER2-
enriched subtype, which showed little evidence of protection in either univariable or
multivariable MR, potentially reflecting its distinct biology and the clinical observation that
overweight and obesity can worsen prognosis in early-stage HER2-positive breast cancer (*46*).
Lacking hormonal regulation, HER2-enriched tumours that depend on aberrant HER2 pathway
activation may be less affected by adiposity-related changes in oestrogen, SHBG, or IGF-1. In
contrast, Luminal B-like (HER2+) tumours appeared to retain evidence of a residual protective
effect across the full reproductive-life window (menarche to <40 years), even after adjustment
for prepubertal body size. This difference may reflect the continued influence of hormone-
dependent pathways in Luminal B-like (HER2+), which could mediate BMI-related protection
through endocrine or metabolic mechanisms despite HER2 expression. Previous MR studies of
childhood body size support such subtype-specific mechanisms; for example, mammographic
density, particularly dense area, appears to mediate much of the protective effect for ER-
positive but not ER-negative breast cancer (*32*), and hormonal mediators such as IGF-1 and
SHBG appear relevant mainly for ER-positive disease (*13*). These findings underscore the
importance of considering breast cancer subtypes when evaluating the long-term effects of
adiposity across the lifecourse.
434
This study is an important analysis with multiple strengths. It focuses on a previously
unexamined life stage – the period between menarche and under 40 years in nulliparous
women – to investigate the impact of increased BMI on breast cancer risk using causal
inference methods. By examining this life stage, we provide evidence on how adiposity before
and during early reproductive life may influence breast cancer development. This focus also
minimises potential confounding from the physiological changes associated with a first
pregnancy, allowing clearer interpretation of life-stage-specific effects. To strengthen the
analysis, we integrated data from five large European longitudinal cohort studies. This
approach allowed us to gain key insights into the consistency of BMI-related genetic effects
across different stages of life. In addition, these data are not only useful for this particular study
but also offer a valuable resource for future research into the effects of BMI in women at this
life stage on other health outcomes.
447
This study has several limitations that should be considered when interpreting the findings.
First, low conditional F-statistics were observed in the MVMR analysis, indicating potential for

weak instrument bias. As a result, our MVMR findings should be interpreted with some caution.
However, the pattern of attenuation observed when adjusting for pre-pubertal body size was
not replicated when adjusting for later life adult body size, despite both exposures being
derived from GWAS with similar sample sizes and instrument strength. This asymmetry
supports the interpretation that the differences in effect estimates are unlikely to be driven by
weak instrument bias alone and likely reflect biologically distinct influences of body size at
different developmental stages. In addition, while we combined data from five large European
longitudinal cohorts, the sample size remains smaller (N=56,628) than that available for
comparable measures of prepubertal and later life body size derived using in UK Biobank data
(N=246,511). This reduced sample size may limit statistical power for detecting smaller effect
sizes. Second, we used a prepubertal GWAS based on reported body size rather than measured
BMI, as it offered a much larger sample size than any other GWAS of BMI at this life stage.
However, this choice may distort MVMR analysis due to measurement error or differences in
variance of effect sizes. Future work to precisely estimate childhood body size genetic effects
are warranted. Third, there is the possibility of participant overlap between the HUNT and
MoBa cohorts. The HUNT Study began in 1984-86, recruiting adults aged ≥20 in Nord-
Trøndelag County across four cycles for over 30 years (*47*). Its Young-HUNT sub-studies
recruited adolescents aged 13-19 in four waves between 1995 and 2019. MoBa, in contrast,
recruited pregnant women nationally between 1999 and 2008 via routine prenatal care (*48*).
Although up to 10% of MoBa participants resided in the Nord-Trøndelag catchment area, the
differing recruitment criteria and time frames mean that any overlap with HUNT participants
is expected to be minimal and unlikely to materially influence the analyses. Some participants
in HUNT may have also participated in MoBa, which could introduce a degree of sample
duplication. Fourth, the inclusion criteria for this study resulted in substantially smaller analytic
samples compared to the total number of participants enrolled in each cohort. Although
genotyping was not based on specific phenotypes, we acknowledge that, as in all large-scale
genetic studies, selection bias due to differential data availability may still be present. Lastly,
as our analysis was restricted to individuals of European ancestry, the generalisability of our
findings to other populations is limited. Further research is needed to confirm these findings
in more diverse populations.
480
481 **Conclusion**
482
This study offers important insights into the genetic influences on BMI across different life
stages and its causal relationship with breast cancer risk, focusing on the period between
menarche and under 40 years in nulliparous women as a key window of susceptibility. While
higher BMI in this interval appeared strongly protective against breast cancer in univariable
analyses, the effect substantially, though not entirely, attenutated after accounting for
childhood body size, used as a proxy for BMI. This pattern suggests that the protection may
arise from the combined influence of greater adiposity in both childhood and early adulthood.

These results have important implications for breast cancer prevention, underscoring earlier
life stages as critical periods for potential interventions.

Materials and methods.

This study adheres to the Strengthening The Reporting of Observational Studies in
Epidemiology Using Mendelian Randomisation (STROBE-MR) guidelines (Table S9).

<u>Data sources and study design</u>

Inclusion criteria and participating cohorts

This study included five large, population-based prospective cohorts with available genomic
and phenotypic BMI data from nulliparous women between menarche and age <40 years: the
Avon Longitudinal Study of Parents and Children (ALSPAC), the Trøndelag Health Study (HUNT),
the Norwegian Mother, Father and Child Cohort Study (MoBa), Generation R, and Generation
Scotland. Participant selection is shown in Figure 1.

ALSPAC. ALSPAC is a birth cohort which enrolled 14,541 pregnant women living in Avon,
England with expected dates of delivery between April 1, 1991, and December 31, 1992 (the
estimated recruitment rate of those eligible was 80%) (*49-51*). Further enrolments after 1998
resulted in a baseline sample of 14,901 children alive at one year of age. Some study data were
collected and managed using Research Electronic Data Capture (REDCap) electronic data
capture tools hosted at the University of Bristol (*52*). Please note that the study website
contains details of all the data that is available through a fully searchable data dictionary and
variable search tool: http://www.bristol.ac.uk/alspac/researchers/our-data/. We used data
collected on women prior to pregnancy and their daughters in the 17 and 24-year follow up
groups that had information on genotype, menarche, BMI and age. We included 3,125 ALSPAC
mothers and 3,496 daughters from the offspring generation in the age-stratified analysis. In
the analysis focused on individuals between menarche and first birth (if pregnancy occurred
within this timeframe), we included 3,125 ALSPAC mothers and 1,922 daughters.

HUNT. HUNT is a cohort study of the adult population in Trøndelag County, Norway, and
comprises ~230,000 individuals aged ≥20 years (*47, 53*). Individuals were recruited in four
surveys from 1984–2019, of which the HUNT2 and HUNT3 surveys were included in the
present study. Invitee participation rates were 69% and 54%, respectively. Data on perinatal
outcomes are available via linkage to the Medical Birth Registry of Norway (MBRN) (*54*) for
individuals born from 1967 onwards. The full recruited sample of mothers was 64,098. A total
of 69,716 offspring were available in HUNT, with genotype and measured phenotype
information, of which 36,938 were female (*55, 56*). A total of 7,683 individuals were used in
this study.

MoBa. MoBa is a population-based pregnancy cohort study conducted by the Norwegian
Institute of Public Health (*48*). Participants were recruited from all over Norway from 1999 to
2008, with 41% of all pregnant women invited consenting to participate. Blood samples were
obtained from both parents during pregnancy and from mothers and children (umbilical cord)
at birth (*57*). The first child was born in October 1999 and the last in July 2009. The cohort
includes approximately 114,500 children, 95,200 mothers, and 75,200 fathers. Additionally,
MoBa was linked to data from the Medical Birth Registry (MBRN), a national health registry
containing information about all births in Norway from 1967 onwards (*54*). This analysis used
a total of 31,471 MoBa first time mothers and 7,216 daughters from the offspring generation
with information on genotype, menarche, BMI, age and parity.
541
Generation R. The Generation R Study is a population-based prospective cohort from fetal life
onwards in Rotterdam, the Netherlands (*58*). Women with an expected delivery date between
April 2002 and January 2006 living in Rotterdam were eligible to enrol the study, and written
informed consent was obtained from all participants. A total 9,778 mothers, who gave birth to
9,749 live-born children, enrolled in the study. Genotype data were available for a total of
7,236 mothers, of which 3,450 were first-time mothers of singleton children and had
information on pre-pregnancy BMI (*59*). Maternal age and pre-pregnancy weight were
reported by the mother and height was measured at intake. A total of 2,396 women
contributed to this GWAS.
551
Generation Scotland. Generation Scotland is a population-based cohort with ~20,000
participants from across Scotland, aged between 18 and 98 years. During 2006 to 2010,
potential participants (aged 35–65 years) were identified and invited to join at random from
collaborating general medical practices in Scotland. Participants were asked to identify ≥1 first-
degree relatives aged ≥18 years who would also be able to participate. Subsequently,
participants attended a staffed research clinic, completed a health questionnaire, and had
physical and clinical characteristics measured according to a standardized protocol. Fasting
blood and urine samples were collected, according to standard operating procedures. The full
recruited sample of female participants was 14,152, of which 3,059 were included in this study
and 2,815 contributed to the GWAS.
562
Given the focus of the research question, only female participants were included in the GWAS.
Inclusion criteria required that participants had genotype data that passed quality control, had
reached menarche, and had BMI measured while still nulliparous. For mothers in birth cohorts,
this corresponded to pre-pregnancy BMI at the time of the index pregnancy, provided they had
not given birth previously. Participants also needed to have complete covariate information.
Analyses were further restricted to individuals aged under 40 to focus on early adulthood and
the reproductive years. To minimise potential population stratification bias, we further limited
the sample to participants of European genetic ancestry.
571

Genotyping, quality control and imputation in each cohort

Genotyping, quality control and imputation for each cohort are described in detail in Supplementary Text and elsewhere (*56, 59-61*). Briefly, participants were genotyped using genome-wide SNP arrays, and imputation was performed using standard reference panels following cohort-specific quality control (QC) protocols. ALSPAC mothers and children were genotyped using Illumina Human660K and HumanHap550 arrays, respectively, with imputation via Haplotype Reference Consortium (HRC) v1.1. HUNT samples were genotyped using three Illumina HumanCoreExome arrays, with imputation performed using Minimac3 and a customized HRC v1.1 reference panel (*56, 60*). MoBa sampels were genotyped across 24 batches with varying selection criteria, centers, and arrays. The European Genome-Phenome Archive HRC v1.1 (Study ID EGAS00001001710) was used for phasing and imputation (*48, 61*). Generation R mothers were genotyped using Illumina GSA-MD 2.0 and 3.0 arrays, with imputation against the 1000 Genomes Phase 3 v5 reference panel (*58, 59*). Generation Scotland samples were genotyped using the Illumina HumanOmniExpressExome-8v1 chip, with imputation via HRC.r1-1 on the Sanger Imputation Server.

Statistical methods

Lifestage-stratified genome-wide association studies (GWAS) and meta-analysis

We aimed to establish lifestage-specific genetic effect profiles for BMI. This was to (i) assess the consistency of genetic variant effects on BMI across different life stages (including prepubertal and later life adulthood, where body size was used as a proxy for BMI based on previously derived genome-wide association studies (GWAS) from UK Biobank data (*14*)) and (ii) applying these profiles in downstream lifecourse MR analyses. To achieve this, we conducted GWAS on lifestage-stratified BMI values across life stage that has not been previously investigated. Specifically, separate GWAS analyses were run on nulliparous women between menarche and <40 years. These analyses were further stratified into three life stages: <20 years, 20 to <30 years, and 30 to <40 years. We define these as life stages, as they are anchored to each individual's age at menarche – a biological milestone that varies between individuals – rather than being defined by absolute age alone. For BMI measurements from mothers in birth cohorts, we extracted pre-pregnancy data from women who had not given birth previously. For cohorts with repeat measures within a single life stage (e.g., menarche to <40 years), we selected the measure with the largest sample size (e.g., ALSPAC offspring BMI data from menarche to <20-year-olds). A complete-case approach was used, excluding individuals with missing values from the analysis. Due to the skewed distribution of BMI in the data, a natural log transformation was applied prior to running the GWAS analyses within each cohort. Each cohort followed a shared GWAS framework using GCTA v1.93.2beta (*62*). While general quality control (QC) guidelines and analysis scripts were provided via a GitHub

repository, individual studies conducted pre-imputation QC independently, applying thresholds appropriate to their cohort data (Supplementary Text and elsewhere (*56, 59-61*)). All analyses were restricted post hoc to common genetic variants with a minor allele frequency (MAF) ≥ 0.01. Genome-wide association analyses were conducted using GCTA's *fastGWA* linear mixed model (*63*). To adjust for related individuals (e.g. mothers and daughters or other close relatives), a genetic relationship matrix (GRM) was constructed from participants and converted into a sparse GRM using a relatedness threshold of 0.05. Age and the top 20 genetic principal components were included as covariates, with the principal components adjusting for population structure.

We meta-analysed summary statistics from the five cohorts for each lifestage-specific GWAS separately, using a fixed effects model employed in METAL version 2020-05-05 (*64*). We carried out further standard quality control QC procedures (*65*) including tests for bias due to population structure (genomic control inflation factor [λ] and Linkage Disequilibrium Score Regression [LDSC] (*66*)). We also estimated SNP heritability and assessed genetic correlations between our meta-analysed GWAS and GWAS derived using UK Biobank data of prepubertal body size and later life adult body size (*14*). Analyses were performed using the LDSC software v1.0.0 (https://github.com/bulik/ldsc) employing default parameters. We used linkage disequilibrium (LD) scores from European participants of the 1000 genomes project that can be downloaded from the LDSC website. We generated Manhattan plots which contain horizontal lines drawn at $-\log10(1\times10^{-5})$ for "suggestive associations" and $-\log10(5\times10^{-8})$ for the 'genome-wide significant' threshold and QQ plots (Figure S2-S5) (*67*).

We used LD clumping with an r^2 threshold of 0.001 and a p-value threshold of 5×10^{-8} to select a set of independent instruments for BMI at each life stage. This was performed using PLINK (*68*) and genotype data from European individuals from phase 3 v5 enrolled in the 1000 genomes project as a reference panel (*69*).

We visualised the life stage-specific effect trajectories of these SNPs at each life stage (menarche to <20 years, 20 to <30 years and 30 to <40 years), with point size inversely proportional to the standard error of the effect estimate. We focused exclusively on SNPs derived from the life stages analysed in this study and did not include those from other studies due to differences in effect size scales. For example, body size measures for prepubertal and later adulthood stages, derived from UK Biobank data, were based on body size categories rather than BMI, making direct comparisons inconsistent (*14*).

Publicly available genome-wide association study (GWAS) data

We used publicly available breast cancer data from the Breast Cancer Association Consortium (BCAC) from 2017 (N = 228,951; ER+/ER- samples, extracted from OpenGWAS under IDs: ieu-a-1127, ieu-a-1128) (*28*) and the latest release of BCAC from 2020 (N = 247,173; overall sample

and five molecular subtypes: Luminal A-like, Luminal B-like (HER2-positive), Luminal B (HER2-negative-like), HER2-enriched, and triple-negative breast cancer (*29*) (details in Table S10). The 2017 dataset included 69,501 ER+ cases and 21,468 ER- cases, with 105,974 shared controls. The 2020 dataset included 63,767 Luminal A-like cases, 15,942 Luminal B-like (HER2-positive) cases, 15,942 Luminal B (HER2-negative-like cases, 10,628 HER2-enriched cases, and 8,602 triple-negative breast cancer (TNBC) cases, all with 91,477 controls. Luminal A-like tumours are characterized by ER+ and/or PR+, HER2- status, and low histologic grade (grade 1-2); Luminal B-like (HER2+) tumours are characterized by ER+ and/or PR+, and HER2+ status; Luminal B/HER2-negative-like tumours are characterized by ER+ and/or PR+, HER2- status, and high histologic grade (grade 3); HER2-enriched-like tumours are defined as HER2+, ER−, and PR−; and triple-negative tumours are defined as ER-, PR-, and HER2-. The cohort design and genotyping protocol details are described elsewhere (bcac.ccge.medschl.cam.ac.uk/bcac-groups/study-groups/, bcac.ccge.medschl.cam.ac.uk/bcacdata/). The study groups in the BCAC consortium do not include ALSPAC, HUNT, MoBa, Generation R, Generation Scotland or UK Biobank cohorts.

For comparative purposes, we utilised previously conducted GWASs of prepubertal and later life adult body size, used as a proxy for BMI, previously undertaken in the UK Biobank study on 246,511 females. These GWAS represent the largest available sample size for body size in these life stages. GWASs were adjusted for age and genotyping chip and genetic variants were selected based on $P<5\times10^{-8}$ and $r^2<0.001$ (*14, 70, 71*). UK Biobank data were collected between 2006 and 2010 on individuals aged between 40 and 69 years old at baseline, including data from clinical examinations, assays of biological samples, detailed information on self-reported health characteristics, and genome-wide genotyping, using a prospective cohort study design (*71*). The prepubertal body size measure utilised recall questionnaire data, involving responses from adult participants who were asked whether, compared to the average, they were 'thinner', 'about average' or 'plumper', when they were aged 10 years old. The adult body size variable was derived using clinically measured body mass index (BMI) data (mean age 56.5 years). It was then separated into a 3-tier variable using the same categories as the childhood body size measure for comparability; "thinner" (21.1 kg/m^2-25 kg/m^2), "about average" (25 kg/m^2-31.7 kg/m^2) and "plumper" (31.7 kg/m^2-59.9 kg/m^2) (*14*). These scores have been independently validated in three distinct cohorts, providing verification that these genetic instruments can reliably separate childhood and adult BMI (*14, 72, 73*).

To disentangle whether our results were influenced by age at menarche, we used publicly available data (Age when periods started (menarche)) from the UK Biobank cohort where female individuals were asked 'How old were you when your periods started?'. This GWAS was conducted in 2014 (N=182,416, extracted from OpenGWAS under ID: ieu-a-1095)). To investigate the potential for collider bias resulting from restricting our analyses to nulliparous women we used publicly available parity data (Number of live births) from the UK Biobank cohort from 2018 (N=250,782, extracted from OpenGWAS under ID: ukb-b-1209). This

695 phenotype includes individuals with zero live births, thereby capturing variation from
696 nulliparity onwards and serving as a useful proxy for parity-related bias.
697
698 *Lifecourse Mendelian randomization (MR) analysis*
699
Our primary two-sample MR analyses used the inverse variance weighted (IVW) estimator,
implemented in the TwoSampleMR R package (*74*). When genetic variants are used as
instrumental variables in MR, the assumptions of instrumental variables must be met, i.e., the
genetic variants used must (i) be strongly associated with the exposure of interest
("relevance"), (ii) not share common causes with the outcome ("independence"), and (iii) not
affect the outcome other than through the exposure ("exclusion-restriction") (*75*). We
conducted sensitivity analyses, which relax the assumptions made about horizontal pleiotropy,
including MR Egger regression (*76*), and the weighted median-based estimator (*77*). We also
applied Steiger filtering (*78*) to test the direction of causality between BMI between menarche
and first birth and breast cancer risk, by assessing whether the genetic instruments explained
more variance in the exposure than in the outcome. In addition we conducted analyses using
the MR-RAPS method which is robust to weak instruments and systematic pleiotropy (*79*). To
allow the inclusion of a larger set of instruments, we applied a liberal SNP selection threshold
of $P<1\times10^{-5}$. We ran IVW multivariable MR (MVMR), an extension of MR that employs multiple
genetic variants associated with multiple measured risk factors, to calculate the direct and
indirect effects of BMI between menarche and first birth on breast cancer outcomes. For each
MVMR model, we included all SNPs associated with either of the two traits, encompassing both
trait-specific (G1 and G2) and shared (G12) variants, as illustrated in Figures 2B and 2C. Genetic
variants associated with each exposure were first pruned for LD to ensure instrument
independence. The resulting SNP lists were then combined across exposures, and any duplicate
variants present in both instruments were retained only once in the initial combined set. This
full combined list was then re-pruned for LD to further ensure independence across all
instruments used in the MVMR analysis. This final pruned set was then used to extract
harmonised summary statistics for all traits. As the MVMR framework accounts for correlations
between exposures and accommodates pleiotropy, this approach supports estimation of
exposure-specific effects and facilitates clearer interpretation of the independent
contributions of each exposure.
727
728
729 This analysis accounted for prepubertal and later life adult body size separately (Figures 5A, B
730 and C). These two additional time points were not included together in a single model due to
731 the risk of weak instrument bias. Instrument strength was evaluated using the two-sample
732 conditional *F*-statistic described elsewhere (*80*).
733
To improve interpretability and biological relevance, all MR effect estimates have been scaled
to represent the effect per one standard deviation (SD) increase in log-tranformed BMI at each

of the life stages. In addition, these estimates reflect the effect of genetic liability to BMI over
particular life stages and should not be interpreted as equivalent to the effect size or duration
of a time-limited intervention (*81*). This distinction is important when considering the clinical
or public health implications of our findings.
740

741
742
Figure 5. Directed acyclic graphs indicating three scenarios to explain the causal effect between BMI in
nulliparous women between menarche and <40 years and breast cancer in later life. A. BMI in
nulliparous women between menarche and <40 years has a total causal effect on breast cancer. B. BMI
in nulliparous women between menarche and <40 years has a total causal effect on breast cancer,
independent of prepubertal body size. C. BMI in nulliparous women between menarche and <40 years
has a total causal effect on breast cancer, independent of later life adult body size.
749

Sensitivity analyses

To minimise pregnancy-related confounding, we restricted the BMI exposure GWAS to nulliparous women, enabling a clearer assessment of BMI's direct influence across life stages. In contrast, the breast cancer outcome GWAS included both nulliparous and parous women. This discrepancy in selection mechanisms introduces potential selection bias in the genetic effect estimates for BMI but not for breast cancer. Specifically, conditioning on parity in the BMI GWAS may induce bias in the estimated SNP effects on BMI ($\hat{\beta}_{Gx}$), whereas breast cancer estimates ($\hat{\beta}_{Gy}$), remain unaffected as parity was not conditioned on in the outcome GWAS (Eq. 1).

In this two-sample MR setting, the MR estimate is given by:

(Eq. 1)

$$\hat{\beta}_{MR} = \frac{\hat{\beta}_{Gy}}{\hat{\beta}_{Gx}}$$

Where:

$$E(\hat{\beta}_{Gx}) = \beta_{Gx} + \text{bias}$$

$$E(\hat{\beta}_{Gy}) = \beta_{Gy}$$

Since $\hat{\beta}_{Gy}$ is not subject to the same selection mechanism and there is no reason to assume that the selection-induced bias in β_{Gx} is correlated with $\hat{\beta}_{Gy}$, a major spurious association in the MR analysis is unlikely. However, selection bias in the BMI GWAS could distort the MR estimate, with the direction and magnitude depending on whether and how BMI influences parity within the restricted sample. In an extreme scenario it could induce false positive associations with BMI that arise due to collider bias though this is unlikely at current sample sizes.

To empirically assess this, we performed univariable MR analyses estimating the effect of parity on BMI in nulliparous women across different life stages (menarche to <40 years, <20 years, 20 to <30 years, and 30 to <40 years). While parity itself cannot causally influence BMI in nulliparous women, genetic variants associated with parity may exhibit pleiotropic effects on BMI through shared metabolic and reproductive pathways. If these parity-associated variants also influence BMI within our restricted sample, it would suggest selection bias related to reproductive behaviour, implying that conditioning on parity in the BMI GWAS may have introduced collider bias. We additionally conducted the reverse analysis, estimating the effect of early-life BMI-associated variants on parity, to assess the potential for bias in the opposite direction.

In addition, a later onset of menarche has been linked to a reduced risk of breast cancer (*82,*
83). Childhood body size has been shown to accelerate the timing of menarche, whilst an
earlier menarche increases the likelihood of increased body size in adulthood (*84, 85*). With
these traits sharing a complex and interconnected relationship, we conduct sensitivity analyses
estimating the effect of BMI in the lifestages analysed in nulliparous women on overall breast
cancer accounting for age at menarche in MVMR analyses. Age at menarche is treated as a
confounder, given its influence both BMI and breast cancer risk through hormonal and
metabolic pathways. Including it in the MVMR model ensures that observed BMI effects are
not simply a reflection of differences in pubertal timing. However, we note that MVMR
adjustment for age at menarche is complicated by the substantial genetic overlap between
prepubertal BMI and menarche timing (*33*).

We conducted statistical analyses in R version 4.3.3 (*86*).

References.

1.	M. Arnold et al., Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast 66, 15-23 (2022).
2.	. (Updated June 2024.).
3.	Y. Liu et al., Physical activity from menarche to first pregnancy and risk of breast cancer. International Journal of Cancer 139, 1223-1230 (2016).
4.	G. A. Colditz, K. Bohlke, C. S. Berkey, Breast cancer risk accumulation starts early: prevention must also. Breast Cancer Res Treat 145, 567-579 (2014).
5.	M. Ciwinska et al., Mechanisms that clear mutations drive field cancerization in mammary tissue. Nature 633, 198-206 (2024).
6.	Y. Liu et al., Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk. J Natl Cancer Inst 105, 1571-1578 (2013).
7.	Alcohol consumption and ethyl carbamate. IARC Monogr Eval Carcinog Risks Hum 96, 3-1383 (2010).
8.	G. Davey Smith, S. Ebrahim, 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32, 1-22 (2003).
9.	E. Sanderson et al., Mendelian randomization. Nat Rev Methods Primers 2, (2022).
10.	G. M. Power et al., Methodological approaches, challenges, and opportunities in the application of Mendelian randomisation to lifecourse epidemiology: A systematic literature review. Eur J Epidemiol 39, 501-520 (2024).
11.	E. Sanderson, G. Davey Smith, F. Windmeijer, J. Bowden, An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol 48, 713-727 (2019).
12.	E. Sanderson, T. G. Richardson, T. T. Morris, K. Tilling, G. Davey Smith, Estimation of causal effects of a time-varying exposure at multiple time points through multivariable mendelian randomization. PLoS Genet 18, e1010290 (2022).
13.	M. Vabistsevits et al., Deciphering how early life adiposity influences breast cancer risk using Mendelian randomization. Commun Biol 5, 337 (2022).
14.	T. G. Richardson, E. Sanderson, B. Elsworth, K. Tilling, G. Davey Smith, Use of genetic variation to separate the effects of early and later life adiposity on disease risk: mendelian randomisation study. BMJ 369, m1203 (2020).
15.	Y. Hao et al., Reassessing the causal role of obesity in breast cancer susceptibility: a comprehensive multivariable Mendelian randomization investigating the distribution and timing of exposure. Int J Epidemiol 52, 58-70 (2023).
16.	G. M. Power et al., A structural mean modelling Mendelian randomization approach to investigate the lifecourse effect of adiposity: applied and methodological considerations. American Journal of Epidemiology, (2025).
17.	B. W. Jensen et al., Childhood body mass index trajectories, adult-onset type 2 diabetes, and obesity-related cancers. J Natl Cancer Inst 115, 43-51 (2023).
18.	G. Fagherazzi, G. Guillas, M.-C. Boutron-Ruault, F. Clavel-Chapelon, S. Mesrine, Body shape throughout life and the risk for breast cancer at adulthood in the French E3N cohort. European Journal of Cancer Prevention 22, 29-37 (2013).
19.	M. Song et al., Trajectory of body shape across the lifespan and cancer risk. Int J Cancer 138, 2383-2395 (2016).

20.   T. O. Yang et al., Body size in early life and the risk of postmenopausal breast cancer.
BMC cancer 22, 232 (2022).

21.   A. Llewellyn, M. Simmonds, C. G. Owen, N. Woolacott, Childhood obesity as a predictor
of morbidity in adulthood: a systematic review and meta-analysis. Obesity reviews 17,
56-67 (2016).

22.   D. Byun et al., Early-life body mass index and risks of breast, endometrial, and ovarian
cancers: a dose-response meta-analysis of prospective studies. Br J Cancer 126, 664-
672 (2022).

23.   Z. J. Andersen et al., Birth weight, childhood body mass index, and height in relation to
mammographic density and breast cancer: a register-based cohort study. Breast
Cancer Research 16, R4 (2014).

24.   T. G. Richardson, H. Urquijo, M. V. Holmes, G. Davey Smith, Leveraging family history
data to disentangle time-varying effects on disease risk using lifecourse mendelian
randomization. European Journal of Epidemiology 38, 765-769 (2023).

25.   C. M. Schooling, K. Fei, J. V. Zhao, Selection bias as an explanation for the observed
protective association of childhood adiposity with breast cancer. J Clin Epidemiol 164,
104-111 (2023).

26.   A. Gkatzionis, S. R. Seaman, R. A. Hughes, K. Tilling, Relationship between collider bias
and interactions on the log-additive scale. Stat Methods Med Res, 9622802241306860
(2025).

27.   G. M. Power, E. Sanderson, G. Davey Smith, G. Hemani, Selection bias is unlikely to fully
explain the protective effect of childhood adiposity on breast cancer risk. Zenodo.,
(2025).

28.   K. Michailidou et al., Association analysis identifies 65 new breast cancer risk loci.
Nature 551, 92-94 (2017).

29.   H. Zhang et al., Genome-wide association study identifies 32 novel breast cancer
susceptibility loci from overall and subtype-specific analyses. Nat Genet 52, 572-581
(2020).

30.   J. Zheng et al., LD Hub: a centralized database and web interface to perform LD score
regression that maximizes the potential of summary level GWAS data for SNP
heritability and genetic correlation analysis. Bioinformatics 33, 272-279 (2017).

31.   M. R. Munafò, K. Tilling, A. E. Taylor, D. M. Evans, G. Davey Smith, Collider scope: when
selection bias can substantially influence observed associations. Int J Epidemiol 47, 226-
235 (2018).

32.   M. Vabistsevits et al., Mammographic density mediates the protective effect of early-
life body size on breast cancer risk. Nat Commun 15, 4021 (2024).

33.   K. A. Kentistou et al., The role of common and rare genetic variation on adiposity across
childhood. medRxiv, 2025.2005.2013.25327505 (2025).

34.   K. A. Kentistou et al., Understanding the genetic complexity of puberty timing across
the allele frequency spectrum. Nat Genet 56, 1397-1411 (2024).

35.   K. Silventoinen, A. Jelenkovic, T. Palviainen, L. Dunkel, J. Kaprio, The Association
Between Puberty Timing and Body Mass Index in a Longitudinal Setting: The
Contribution of Genetic Factors. Behavior Genetics 52, 186-194 (2022).

36.   R. Lloyd et al., The Prospective Association between Early Life Growth and Breast
Density in Young Adult Women. Cancers. 2024 (10.3390/cancers16132418).

37.   T. X. M. Tran et al., Adiposity, Body Composition Measures, and Breast Cancer Risk in
Korean Premenopausal Women. JAMA Network Open 7, e245423-e245423 (2024).

38.   P. A. van den Brandt et al., Pooled analysis of prospective cohort studies on height,
897   weight, and breast cancer risk. Am J Epidemiol 152, 514-527 (2000).
898   39.   P. A. van den Brandt et al., Body size and weight change over adulthood and risk of
899   breast cancer by menopausal and hormone receptor status: a pooled analysis of 20
900   prospective cohort studies. Eur J Epidemiol 36, 37-55 (2021).
901   40.   T. Dehesh et al., The relation between obesity and breast cancer risk in women by
902   considering menstruation status and geographical variations: a systematic review and
903   meta-analysis. BMC Women's Health 23, 392 (2023).
904   41.   C. M. Friedenreich, Review of anthropometric factors and breast cancer risk. Eur J
905   Cancer Prev 10, 15-32 (2001).
906   42.   M. L. Neuhouser et al., Overweight, Obesity, and Postmenopausal Invasive Breast
907   Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical
908   Trials. JAMA Oncol 1, 611-621 (2015).
909   43.   I. Glassman et al., The Role of Obesity in Breast Cancer Pathogenesis. Cells 12, (2023).
910   44.   R. S. Cecchini et al., Body mass index and the risk for developing invasive breast cancer
911   among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer
912   Prev Res (Phila) 5, 583-592 (2012).
913   45.   P. Zhao, N. Xia, H. Zhang, T. Deng, The Metabolic Syndrome Is a Risk Factor for Breast
914   Cancer: A Systematic Review and Meta-Analysis. Obes Facts 13, 384-396 (2020).
915   46.   F. Ligorio et al., Prognostic impact of body mass index (BMI) in HER2+ breast cancer
916   treated with anti-HER2 therapies: from preclinical rationale to clinical implications.
917   Ther Adv Med Oncol 14, 17588359221079123 (2022).
918   47.   B. O. Åsvold et al., Cohort Profile Update: The HUNT Study, Norway. International
919   Journal of Epidemiology 52, e80-e91 (2022).
920   48.   P. Magnus et al., Cohort Profile Update: The Norwegian Mother and Child Cohort Study
921   (MoBa). International Journal of Epidemiology 45, 382-388 (2016).
922   49.   A. Fraser et al., Cohort Profile: the Avon Longitudinal Study of Parents and Children:
923   ALSPAC mothers cohort. Int J Epidemiol 42, 97-110 (2013).
924   50.   A. Boyd et al., Cohort Profile: the 'children of the 90s'--the index offspring of the Avon
925   Longitudinal Study of Parents and Children. Int J Epidemiol 42, 111-127 (2013).
926   51.   K. Northstone et al., The Avon Longitudinal Study of Parents and Children (ALSPAC): an
927   update on the enrolled sample of index children in 2019. Wellcome Open Res 4, 51
928   (2019).
929   52.   P. A. Harris et al., Research electronic data capture (REDCap)--a metadata-driven
930   methodology and workflow process for providing translational research informatics
931   support. J Biomed Inform 42, 377-381 (2009).
932   53.   S. Krokstad et al., Cohort Profile: the HUNT Study, Norway. Int J Epidemiol 42, 968-977
933   (2013).
934   54.   L. M. Irgens, The Medical Birth Registry of Norway. Epidemiological research and
935   surveillance throughout 30 years. Acta Obstet Gynecol Scand 79, 435-439 (2000).
936   55.   G.-H. Moen et al., Mendelian randomization study of maternal influences on
937   birthweight and future cardiometabolic risk in the HUNT cohort. Nature
938   Communications 11, 5404 (2020).
939   56.   B. M. Brumpton et al., The HUNT study: A population-based cohort for genetic
940   research. Cell Genom 2, 100193 (2022).
941   57.   L. Paltiel et al., The biobank of the Norwegian Mother and Child Cohort Study – present
942   status. Norsk Epidemiologi 24, (2014).

943   58.   M. N. Kooijman et al., The Generation R Study: design and cohort update 2017. Eur J
944   Epidemiol 31, 1243-1264 (2016).
945   59.   S. Ghatan et al., Genetic Nurture: Estimating the direct genetic effects of pediatric
946   anthropometric traits. medRxiv, 2024.2012.2010.24318796 (2024).
947   60.   M. Næss et al., Data Resource Profile: The HUNT Biobank. Int J Epidemiol 53, (2024).
948   61.   E. C. Corfield et al., The Norwegian Mother, Father, and Child cohort study (MoBa)
949   genotyping   data   resource: MoBaPsychGen   pipeline   v.1.   bioRxiv,
950   2022.2006.2023.496289 (2024).
951   62.   J. Yang, S. H. Lee, M. E. Goddard, P. M. Visscher, GCTA: A Tool for Genome-wide
952   Complex Trait Analysis. The American Journal of Human Genetics 88, 76-82 (2011).
953   63.   L. Jiang et al., A resource-efficient tool for mixed model association analysis of large-
954   scale data. Nature Genetics 51, 1749-1755 (2019).
955   64.   C. J. Willer, Y. Li, G. R. Abecasis, METAL: fast and efficient meta-analysis of genomewide
956   association scans. Bioinformatics 26, 2190-2191 (2010).
957   65.   A. Ani, P. J. van der Most, H. Snieder, A. Vaez, I. M. Nolte, GWASinspector:
958   comprehensive   quality   control   of   genome-wide   association   study   results.
959   Bioinformatics 37, 129-130 (2021).
960   66.   B. K. Bulik-Sullivan et al., LD Score regression distinguishes confounding from
961   polygenicity in genome-wide association studies. Nature genetics 47, 291 (2015).
962   67.   S. S. Paria, S. R. Rahman, K. Adhikari, fastman: A fast algorithm for visualizing GWAS
963   results using Manhattan and Q-Q plots. bioRxiv, 2022.2004.2019.488738 (2022).
964   68.   C. C. Chang et al., Second-generation PLINK: rising to the challenge of larger and richer
965   datasets. Gigascience 4, 7 (2015).
966   69.   G. R. Abecasis et al., An integrated map of genetic variation from 1,092 human
967   genomes. Nature 491, 56-65 (2012).
968   70.   C. Sudlow et al., UK biobank: an open access resource for identifying the causes of a
969   wide range of complex diseases of middle and old age. PLoS Med 12, e1001779 (2015).
970   71.   C. Bycroft et al., The UK Biobank resource with deep phenotyping and genomic data.
971   Nature 562, 203-209 (2018).
972   72.   M. Brandkvist et al., Separating the genetics of childhood and adult obesity: a validation
973   study of genetic scores for body mass index in adolescence and adulthood in the HUNT
974   Study. Hum Mol Genet 29, 3966-3973 (2021).
975   73.   T. G. Richardson et al., Evaluating the direct effects of childhood adiposity on adult
976   systemic   metabolism: a   multivariable   Mendelian   randomization   analysis.   Int   J
977   Epidemiol, (2021).
978   74.   G. Hemani et al., The MR-Base platform supports systematic causal inference across
979   the human phenome. Elife 7, e34408 (2018).
980   75.   R. C. Richmond, G. Davey Smith, Mendelian Randomization: Concepts and Scope. Cold
981   Spring Harb Perspect Med 12, (2022).
982   76.   J. Bowden, G. Davey Smith, S. Burgess, Mendelian randomization with invalid
983   instruments: effect estimation and bias detection through Egger regression.
984   International journal of epidemiology 44, 512-525 (2015).
985   77.   J. Bowden, G. Davey Smith, P. C. Haycock, S. Burgess, Consistent estimation in
986   Mendelian randomization with some invalid instruments using a weighted median
987   estimator. Genetic epidemiology 40, 304-314 (2016).

988   78.   G. Hemani, K. Tilling, G. Davey Smith, Orienting the causal relationship between
989   imprecisely measured traits using GWAS summary data. PLoS Genet 13, e1007081
990   (2017).

991   79.   Q. Zhao, J. Wang, G. Hemani, J. Bowden, D. S. Small, Statistical inference in two-sample
992   summary-data Mendelian randomization using robust adjusted profile score. (2020).

993   80.   E. Sanderson, W. Spiller, J. Bowden, Testing and correcting for weak and pleiotropic
994   instruments in two-sample multivariable Mendelian randomization. Stat Med 40, 5434-
995   5452 (2021).

996   81.   B. Woolf, S. Burgess, The role of estimation in Mendelian randomization: should
997   Mendelian randomization investigations provide estimates? AJE Advances: Research in
998   Epidemiology 1, (2025).

999   82.   Menarche, menopause, and breast cancer risk: individual participant meta-analysis,
1000   including 118 964 women with breast cancer from 117 epidemiological
1001   studies. The Lancet Oncology 13, 1141-1151 (2012).

1002   83.   G. V. Dall, K. L. Britt, Estrogen Effects on the Mammary Gland in Early and Late Life and
1003   Breast Cancer Risk. Front Oncol 7, 110 (2017).

1004   84.   F. Juul, V. W. Chang, P. Brar, N. Parekh, Birth weight, early life weight gain and age at
1005   menarche: a systematic review of longitudinal studies. Obes Rev 18, 1272-1288 (2017).

1006   85.   C. Prince, L. D. Howe, G. C. Sharp, A. Fraser, R. C. Richmond, Establishing the
1007   relationships between adiposity and reproductive factors: a multivariable Mendelian
1008   randomization analysis. BMC Med 21, 350 (2023).

1009   86.   R Core Team. (R Foundation for Statistical Computing, Vienna, Austria, 2020).

1010   87.   R. Wootton, & Havdahl, A. . (2025).

1011

Acknowledgements.

We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. The authors would also like to thank the research participants of the HUNT study which is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU Norwegian University of Science and Technology), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The HUNT genotype quality control and imputation has been conducted by the K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, NTNU. In addition, we are grateful to all the families who took part, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses. The Norwegian Mother, Father and Child (MoBa) Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. We are grateful to all the participating families in Norway who take part in this on-going cohort study. We thank the Norwegian Institute of Public Health (NIPH) for generating genomic data as part of the HARVEST collaboration, supported by the Research Council of Norway (#229624). We also thank the NORMENT Centre for providing genotype data, funded by the Research Council of Norway (#223273), South East Norway Health Authorities and Stiftelsen Kristian Gerhard Jebsen, and conducted by deCODE Genetics. We further thank the Center for Diabetes Research, the University of Bergen for providing genotype data and performing quality control and imputation of the data funded by the ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation, the Research Council of Norway, the Novo Nordisk Foundation, the University of Bergen, and the Western Norway Health Authorities. The MoBa analyses of BMI were carried out as part of the Lifecourse GWAS Consortium through the PsychGen multimorbidity project (REK 2016/1702), and in contribution to the project "Combining Mendelian Randomisation and Depression Trajectories to Better Inform Intervention Timing" (*87*). The MoBa analyses were performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT Department (USIT) (tsd-drift@usit.uio.no). The analyses were performed using resources provided by Sigma2 - the National Infrastructure for High-Performance Computing and Data Storage in Norway. The Generation R Study is conducted by Erasmus MC in close collaboration with the School of Law and Faculty of Social Sciences of the Erasmus University Rotterdam, the Municipal Health Service Rotterdam area, Rotterdam, the Rotterdam Homecare Foundation, Rotterdam, and the Stichting Trombosedienst & Artsenlaboratorium Rijnmond (STAR-MDC), Rotterdam. We gratefully acknowledge the contribution of children and parents, general practitioners, hospitals, midwives, and pharmacies in Rotterdam. The generation and management of GWAS genotype data for the Generation R Study was done at the Human

Genomics Facility, HuGe-F, housed within the Laboratory for Population Genomics of the Department of Internal Medicine at Erasmus MC. Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, The Netherlands. We thank Pascal Arp, Gaby van Dijk, Marijn Verkerk, Samuel Gathan, Dr. Linda Broer and Jard de Vries for their help in creating, managing and QCing the GWAS database.

Funding.

The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. GMP, AH, GL, ES, RR, GH, and GDS were supported by the Integrative Epidemiology Unit which receives funding from the UK Medical Research Council and the University of Bristol (MC_UU_00032/1). GDS conducts research at the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. The genotyping in HUNT was supported by the National Institutes of Health (NIH); University of Michigan; The Research Council of Norway (RCN); The Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint Research Committee between St. Olavs hospital and the Faculty of Medicine and Health Sciences, NTNU. LB, BOA, and BMB work in a research unit financially supported by the Liaison Committee for education, research and innovation in Central Norway and the Joint Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU. This study used data from Medical Birth Registry of Norway (MBRN). Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006] and is currently supported by the Wellcome Trust [216767/Z/19/Z]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award "STratifying Resilience and Depression Longitudinally" (STRADL) Reference 104036/Z/14/Z. CH was supported by an MRC University Unit core grant MC_UU_00007/10 (QTL in Health and Disease program). BLL acknowledges support from the University of Bristol (Vice-Chancellor's Research Fellowship), Academy of Medical Sciences/Wellcome Trust/the Government Department of Business, Energy and Industrial Strategy/British Heart Foundation/Diabetes UK Springboard Award (SBF003/1170), Elizabeth Blackwell Institute for Health Research (University of Bristol), and Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z) and Wellcome Trust Career Development Award (227849/Z/23/Z). AH was supported by the Research Council of Norway (#336085) and the South-Eastern Norway Regional Health Authority (#2020022; #2922083; #2019097; #2018059; #2021045). The general design of the Generation R Study is made possible by financial support from Erasmus MC, University Medical Center Rotterdam, Erasmus University Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw), the Netherlands Organization for Scientific Research (NWO), the Ministry of Health, Welfare and Sport, and the Ministry of

Youth and Families. The parental genotyping in Generation R was supported by the ERC under
the European Union's Horizon 2020 research and innovation programme (iRISK; grant
agreement No 863981). This project received funding from the European Union's Horizon
Europe Research and Innovation Programme under grant agreement nº 101137146 (STAGE
project). UK participants in Horizon Europe Project STAGE are supported by UKRI grant
numbers 10112787 (Beta Technology), 10099041 (University of Bristol) and 10109957
(Imperial College London).

1101

Research Ethics and Informed Consent.
Informed consent for cohort participation was obtained from all participants and ethical
approval was obtained from the Regional Committee for Medical and Health Research Ethics,
Central Norway (REK Central application number 2018/2488) (HUNT), the ALSPAC Ethics and
Law Committee and the Local Research Ethics Committees (ALSPAC), and the Medical Ethical
Committee of Erasmus MC, University Medical Center Rotterdam, approved the study (MEC
198.782/2001/31) (Generation R), and The Regional Committees for Medical and Health
Research Ethics (REK application number 2016/1702) (MoBa). Written consent was obtained
from all participants in Generation Scotland. All components of Generation Scotland received
ethical approval from the NHS Tayside Committee on Medical Research Ethics (REC Reference
Number: 05/S1401/89). Generation Scotland has also been granted Research Tissue Bank
status by the East of Scotland Research Ethics Service (REC Reference Number: 20-ES-0021).

1114

Author Contributions.
Conceptualization: GMP, GDS; Methodology: GMP, GH; Formal analysis: GMP, LB, AMH, CMG,
DM AR; Data curation: GMP, LB, AMH, AMG, AR, ECC; Writing – original draft: GMP; Writing –
review & editing: GMP, LB, AMH, CMG, AR, GL, BLL, ES, RR, ECC, DM, CH, IFM, FR, BOÅ, GH,
JFF, BB, AH, GDS; Visualisation: GMP, Supervision: GDS, GH, AH, BB, JFF, CH; Project
administration: GMP; Funding acquisition: GDS, GH, AH

1121

1122   **Competing interests.**
1123   Daniel McCartney is an employee of Optima Partners Ltd. All authors declare no other
1124   competing interests.

1125

Data and Materials Availability.
Data access for the Avon Longitudinal Study of Parents and Children (ALSPAC) operates via a
managed open access system. Approved proposals are reviewed by the ALSPAC Executive
Committee. Full details are provided in the ALSPAC Data Management Plan
(www.bristol.ac.uk/alspac/researchers/data-access/documents/alspac-data-management-
plan.pdf). Data from the Norwegian Mother, Father and Child (MoBa) Cohort Study is
managed by the Norwegian Institute of Public Health. Access is provided upon approval from
the Regional Committees for Medical and Health Research Ethics (REC), compliance with
GDPR, and data owner approval. Participant consent does not allow individual-level data

storage in repositories or journals. Researchers seeking access for replication must apply via www.helsedata.no. To request access to data from the Trøndelag Health Study (HUNT), researchers affiliated with Norwegian research institutes can apply for the use of HUNT data and biological samples, subject to approval by the Regional Committee for Medical and Health Research Ethics. Researchers from other countries may also apply if collaborating with a Norwegian Principal Investigator. All applications are reviewed by the HUNT Data Access Committee, and successful applicants are required to enter into data access and/or material transfer agreements. Detailed information on the application process, ethical requirements, and available datasets can be found on the HUNT website (www.ntnu.edu/hunt/data). Data from Generation Scotland are available on application to an independent access committee. More information can be found on the Generation Scotland website (www.generationscotland.org). Data from the Generation R Study are available upon reasonable request to the director of the Generation R Study (generationr@erasmusmc.nl), subject to local, national and European rules and regulations.

All genetic instruments derived in this study are in the supplementary tables. Genome-wide association study summary statistics will be made available on a public repository upon publication.

Code provided to collaborators for conducting the GWAS of BMI between menarche and first birth is available at: https://github.com/gracemarionpower/Collaboration_MA_BMI_M2FB.

None of the material has been published or is under consideration for publication elsewhere.